monday.com (NASDAQ:MNDY – Get Free Report) had its price objective increased by investment analysts at Barclays from $300.00 to $325.00 in a report released on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 20.24% from the company’s current price.
MNDY has been the subject of a number of other reports. TD Cowen upped their target price on shares of monday.com from $300.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. Piper Sandler restated an “overweight” rating and set a $300.00 price objective (up from $270.00) on shares of monday.com in a research note on Monday, August 12th. Tigress Financial increased their price objective on shares of monday.com from $280.00 to $340.00 and gave the stock a “buy” rating in a research note on Wednesday, August 21st. William Blair restated an “outperform” rating on shares of monday.com in a research note on Monday, June 24th. Finally, DA Davidson increased their price objective on shares of monday.com from $250.00 to $300.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 25th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, monday.com presently has an average rating of “Moderate Buy” and an average price target of $296.16.
View Our Latest Report on MNDY
monday.com Stock Performance
monday.com (NASDAQ:MNDY – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.23. The firm had revenue of $236.11 million during the quarter, compared to analyst estimates of $227.96 million. monday.com had a net margin of 4.88% and a return on equity of 4.74%. On average, research analysts forecast that monday.com will post 0.49 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Mercer Global Advisors Inc. ADV raised its holdings in monday.com by 4.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 1,124 shares of the company’s stock valued at $271,000 after acquiring an additional 47 shares during the period. Crossmark Global Holdings Inc. raised its holdings in monday.com by 4.0% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 1,303 shares of the company’s stock valued at $314,000 after acquiring an additional 50 shares during the period. FDx Advisors Inc. increased its holdings in shares of monday.com by 4.7% during the second quarter. FDx Advisors Inc. now owns 2,000 shares of the company’s stock worth $482,000 after purchasing an additional 90 shares during the period. Oppenheimer Asset Management Inc. increased its holdings in shares of monday.com by 4.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 2,065 shares of the company’s stock worth $497,000 after purchasing an additional 91 shares during the period. Finally, American International Group Inc. increased its holdings in shares of monday.com by 2.3% during the first quarter. American International Group Inc. now owns 4,550 shares of the company’s stock worth $1,028,000 after purchasing an additional 102 shares during the period. 73.70% of the stock is owned by institutional investors.
About monday.com
monday.com Ltd., together with its subsidiaries, develops software applications in the United States, Europe, the Middle East, Africa, the United Kingdom, and internationally. The company provides Work OS, a cloud-based visual work operating system that consists of modular building blocks used and assembled to create software applications and work management tools.
Further Reading
- Five stocks we like better than monday.com
- How to Invest in the FAANG Stocks
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Are Dividend Achievers? An Introduction
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Quiet Period Expirations Explained
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for monday.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for monday.com and related companies with MarketBeat.com's FREE daily email newsletter.